|
Post by xanet on Jan 8, 2018 23:32:00 GMT -5
Here's to hoping the share price shoots up before the 19th! Stranger things have happened with this stock.
|
|
|
Post by dreamboatcruise on Jan 8, 2018 23:53:45 GMT -5
Here's to hoping the share price shoots up before the 19th! Stranger things have happened with this stock. Would be nice, though I've already mentally written my Jan options off. Those I've held for a long time. I can't fathom why last year I bought some May 2018 when I could have gone longer. I fear those two will expire worthless. With MNKD I think there are two options strategies... very short term on some upcoming event or multiyear leaps.
|
|
|
Post by careful2invest on Jan 9, 2018 0:01:11 GMT -5
Here's to hoping the share price shoots up before the 19th! Stranger things have happened with this stock. Would be nice, though I've already mentally written my Jan options off. Those I've held for a long time. I can't fathom why last year I bought some May 2018 when I could have gone longer. I fear those two will expire worthless. With MNKD I think there are two options strategies... very short term on some upcoming event or multiyear leaps. Good thing that you only bought "two" just in case they "too" expire worthless. I am "too" careful2invest "to" play the options game. GLTA!
|
|
|
Post by dreamboatcruise on Jan 9, 2018 0:08:35 GMT -5
Would be nice, though I've already mentally written my Jan options off. Those I've held for a long time. I can't fathom why last year I bought some May 2018 when I could have gone longer. I fear those two will expire worthless. With MNKD I think there are two options strategies... very short term on some upcoming event or multiyear leaps. Good thing that you only bought "two" just in case they "too" expire worthless. I am "too" careful2invest "to" play the options game. GLTA! If only Fortunately, I have far more Jan 2019 than the 2018s.
|
|
|
Post by buyitonsale on Jan 9, 2018 1:11:05 GMT -5
All we have to offer is best mealtime insulin on the market and the only inhaled insulin on the market...
|
|
|
Post by #NoMoreNeedles on Jan 9, 2018 3:49:20 GMT -5
Hey, what about picking up one of those Sanofi pens at the booth!? LOL
|
|
|
Post by sportsrancho on Jan 9, 2018 7:23:57 GMT -5
|
|
|
Post by casualinvestor on Jan 9, 2018 11:03:08 GMT -5
Victoria, as I recall this was debated earlier on the Board when first mentioned and was shown that after 12.31.18 it went back to $25m. Either way it does not change the cash position much by end of 1st Q with an approximately $30m per month burn rate, as they will need to know how they are funding company moving into Q2. Respectfully, MM My understanding is: At September 30, 2017, the Company’s capital resources consisted of cash and cash equivalents of $20.1 million (http://investors.mannkindcorp.com/secfiling.cfm?filingID=1564590-17-22243&CIK=899460) In Oct they gained $57.7M. With a 10M/month burn rate, they should have had about $47M left in cash at 1/1/18. I can't find anything about changing the reserve. So, yes cash needs to be raised before 3/31/18 assuming they need to have $25M on had then. That will be necessary whether $10M is paid to Deerfield or not
|
|
|
Post by brotherm1 on Jan 9, 2018 11:30:30 GMT -5
The JPM conference will be meaningless if MannKind isn’t presenting. The reason MannKind isn’t presenting is because they don’t have any new data to present. That means none of the ongoing trials will be completed by then... What’s the CEO supposed to do, wander around and tell people “we have some important trials ongoing and have some great preliminary data, but I can’t tell you about it yet...”? What a waste of time... Every minute needs to go towards improving scripts & coverage (instead). Oh
|
|
|
Post by harryx1 on Jan 9, 2018 15:07:43 GMT -5
|
|
|
Post by boca1girl on Jan 9, 2018 19:27:23 GMT -5
Interesting interview of Verily exec at JPM. Mentions their work in Diabetes and mentions partners in Onduo. CNBC - Verily's project baseline: 'Google Maps for health' Verily's project baseline: 'Google Maps for health' CNBC's Meg Tirrell speaks with Verily Chief Medical Officer Dr. Jessica Mega about the role Alphabet plays in the biotech company and what it could mean for the future of medicine. video.cnbc.com/gallery/?video=3000685277
|
|
|
Post by roguesuerte on Jan 10, 2018 22:44:27 GMT -5
I guess MNKD is essentially a fly on the wall at JPM. I think it would have been nice for mgmt. to grab some free press by talking about the label change
and schmooze with some forward looking guidance, anything. If nothing else just to let people know Afrezza is still on the market or to let many know it even
exists. Alot of our problem is lack of awareness and Mgmt certainly not furthering our cause by not presenting.
|
|
|
Post by sla55 on Jan 11, 2018 10:12:18 GMT -5
Comments from Bristol-Myers Squibb (BMY) CEO Giovanni Caforio at the 36th Annual J.P. Morgan Healthcare Brokers Conference:
"Now, here at JPMorgan, let me just make a couple of comments about business development. First of all, it remains a really important priority for us. I know that many of you in the room maybe work with companies that are we are meeting with, that we are patterning with, that we are in discussions with. And I’m quite proud that what I hear from many of our discussions is that because of our priority in business development, because of the strength of our science and the focus of our team increasingly we are becoming a partner of choice to so many companies that have interesting technologies where we have an opportunity to work together.
Our business development strategy will not change. It remains a key pillar of the strategy of the company. We are always looking for assets and technologies that are strategically aligned to our priorities that are scientifically, potentially transformational and obviously for deals that make sense from a financial perspective."
|
|